The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.
Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding .
Notice of Funding Opportunities
Title
Announcement Number
Activity Code
Clinical Trials Status
Expiration Date
Program Official
Sort ascending
Basic Research in Cancer Health Disparities
PAR-21-323 (R21 Clinical Trial Not Allowed)
R21
Clinical Trial Not Allowed
09/08/2024
Asad Umar, D.V.M., Ph.D.
Basic Research in Cancer Health Disparities
PAR-21-324 (R03 Clinical Trial Not Allowed)
R03
Clinical Trial Not Allowed
09/08/2024
Asad Umar, D.V.M., Ph.D.
Biology of Bladder Cancer
PAR-22-218 (R01 Clinical Trial Optional)
R01
Clinical Trial Optional
09/08/2025
Biology of Bladder Cancer
PAR-22-219 (R21 Clinical Trial Optional)
R21
Clinical Trial Optional
09/08/2025
Assay Validation of High Quality Markers for Clinical Studies in Cancer
PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed)
UH2, UH3
Clinical Trial Not Allowed
10/15/2026
Sudhir Srivastava, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer
PAR-23-314 (UH3 Clinical Trials Not Allowed)
UH3
10/15/2026
Sudhir Srivastava, Ph.D., M.P.H.
Mechanisms that Impact Cancer Risk after Bariatric Surgery
PAR-21-332 (R21 Clinical Trial Not Allowed)
R21
Clinical Trial Not Allowed
09/08/2024
Edward Sauter, M.D., Ph.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics
PAR-23-279 (R01 Clinical Trial Optional)
R01
Clinical Trial Optional
01/08/2027
Edward Sauter, M.D., Ph.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics
PAR-23-280 (R21 Clinical Trial Not Allowed)
R21
Clinical Trial Not Allowed
01/08/2027
Edward Sauter, M.D., Ph.D.
Notice of Special Interest (NOSI): Mechanisms Driving Obesity and Prostate Cancer Risk
NOT-CA-23-089
09/08/2024
Edward Sauter, M.D., Ph.D.